Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report (Q42546265)

2 November 2017

title

Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report (English)

1 reference

2 November 2017

1 reference

Sweet RA

1

1 reference

2 November 2017

Pollock BG

2

1 reference

2 November 2017

Mulsant BH

3

1 reference

2 November 2017

Rosen J

4

1 reference

2 November 2017

Lo KH

5

1 reference

2 November 2017

Yao JK

6

1 reference

2 November 2017

Henteleff RA

7

1 reference

2 November 2017

Mazumdar S

8

1 reference

2 November 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

2 November 2017

published in

Biological Psychiatry

1 reference

2 November 2017

volume

42

1 reference

2 November 2017

issue

11

1 reference

2 November 2017

page(s)

1016-1023

1 reference

The value of chemotherapy in senile mental distrubances. Controlled comparison of chlorpromazine, reserpine-pipradrol, and opium.

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Homovanillic acid measurement in clinical research: a review of methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Efficacy of antipsychotic medications in behaviorally disturbed dementia patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Plasma catecholamine metabolites and treatment response at neuroleptic steady state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Are there neurochemical indicators of risk for schizophrenia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Control of exogenous factors affecting plasma homovanillic acid concentration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Plasma homovanillic acid as a predictor of response to neuroleptics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Plasma homovanillic acid concentration and the severity of schizophrenic illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Dopamine in schizophrenia: a review and reconceptualization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients'

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Simultaneous determination of free homovanillic acid, (3-methoxy-4-hydroxyphenyl)ethylene glycol, and vanilmandelic acid in human plasma by high-performance liquid chromatography coupled with dual-electrode coulometric electrochemical detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

The use of trifluoperazine in geriatric patients with chronic brain syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Parkinson's disease in patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Dopamine metabolism and disposition in schizophrenic patients. Studies using debrisoquin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

A metaanalysis of controlled trials of neuroleptic treatment in dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Plasma and CSF HVA before and after pharmacological treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

HALOPERIDOL IN THE PSYCHIATRIC DISORDERS OF OLD AGE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Neuroleptics in the elderly: guidelines for monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Neuroleptic-Induced Parkinsonism in Elderly Patients Diagnosed With Psychotic Major Depression and Dementia of the Alzheimer Type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Multicenter clinicopathological correlation in dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Neuropathologic and neurochemical correlates of psychosis in primary dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

Impact of psychiatric hospitalization on behavioral complications of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900146-7

10.1016/S0006-3223(97)00146-7

7 January 2021

Identifiers

DOI

1 reference

2 November 2017

1 reference